Elevance Health (NYSE:ELV) Price Target Raised to $331.00

Elevance Health (NYSE:ELV) had its price target lifted by equities research analysts at Robert W. Baird from $317.00 to $331.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 1.43% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on ELV. Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Mizuho lowered their price objective on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Jefferies Financial Group reduced their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday. Wells Fargo & Company reduced their target price on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $379.00.

Elevance Health Price Performance

Shares of Elevance Health stock opened at $326.32 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $432.93. The firm has a fifty day moving average price of $308.80 and a two-hundred day moving average price of $331.56. The company has a market cap of $71.68 billion, a PE ratio of 12.99, a price-to-earnings-growth ratio of 1.81 and a beta of 0.49.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the firm earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts expect that Elevance Health will post 25.75 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sound View Wealth Advisors Group LLC boosted its stake in Elevance Health by 3.0% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock worth $354,000 after acquiring an additional 29 shares during the last quarter. Fulton Breakefield Broenniman LLC boosted its stake in Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after acquiring an additional 29 shares during the last quarter. Perigon Wealth Management LLC lifted its stake in Elevance Health by 2.2% in the fourth quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after buying an additional 29 shares in the last quarter. Savvy Advisors Inc. lifted its stake in Elevance Health by 3.2% in the fourth quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after buying an additional 30 shares in the last quarter. Finally, HBK Sorce Advisory LLC lifted its stake in Elevance Health by 4.4% in the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after buying an additional 31 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results beat and management raised full‑year guidance — ELV reported $12.58 EPS (well above consensus) and revenue ahead of expectations; management said results reflect improving claims experience and raised full‑year adjusted EPS guidance. Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: Management lifted 2026 adjusted EPS outlook and flagged 2027 growth — management raised its 2026 adjusted EPS outlook (Seeking Alpha reports a floor of $26.75) and is targeting ~12% EPS growth in 2027, giving investors clearer earnings runway. Elevance Health raises 2026 adjusted EPS outlook to at least $26.75 while targeting at least 12% EPS growth in 2027
• Positive Sentiment: Margin tailwinds from cost control, AI and stronger investment income — commentary emphasized operating discipline and AI integration as drivers of margin expansion; net investment income rose sharply and helped EPS. ELV Q1 deep dive: Operating discipline and AI integration drive margin expansion
• Positive Sentiment: Dividend maintained/income support — Board declared a $1.72 quarterly dividend (yield ~2.1%), which supports income‑oriented holders and signals confidence in cash flow.
• Neutral Sentiment: Analyst/press takeaways and valuation focus — Coverage highlights solid top‑/bottom‑line beats but notes mixed elements (membership trends, expense pressure); some writeups look at valuation after the pullback. A Look At Elevance Health (ELV) Valuation As Mixed Q1 2026 Results Draw Investor Attention
• Negative Sentiment: Shareholder litigation/SEC‑style investor probe announced — Law firm Kirby McInerney has opened an investigation into possible securities law violations by Elevance or senior management; such probes can lead to litigation, settlements or reputational damage and are a near‑term overhang. ELV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Elevance Health, Inc.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.